• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Fractyl Health Inc.

    11/13/24 5:17:27 PM ET
    $GUTS
    Get the next $GUTS alert in real time by email
    SC 13G 1 d863183dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO

    RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO

    13d-2 (b)

    (Amendment No.  )

     

     

    Fractyl Health, Inc.

    (Name of Issuer)

    Common Stock, par value $0.00001 per share

    (Title of Class of Securities)

    35168W103

    (CUSIP Number)

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 35168W103      

    13G

     

     1.   

     Name of Reporting Persons

     

     Mithril LP

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC Use Only

     

     4.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.    

     Sole Voting Power

     

     0

       6.   

     Shared Voting Power

     

     5,160,301 shares of common stock (1)

       7.   

     Sole Dispositive Power

     

     0

       8.   

     Shared Dispositive Power

     

     5,160,301 shares of common stock (1)

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     5,160,301 shares of common stock (1)

    10.  

     Check if the Aggregate Amount in Row 9 Excludes Certain Shares (See Instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row 9

     

     10.8% (2)

    12.  

     Type of Reporting Person (See Instructions)

     

     PN

     

     

    (1)

    All such shares are held of record by Mithril I (as defined in Item 2(a) below). Mithril GP (as defined in Item 2(a) below) is the general partner of Mithril I and Mithril GP may be deemed to have shared voting, investment and dispositive power with respect to these securities. Ajay Royan is the authorized person of Mithril GP. Ajay Royan and Peter Thiel are the members of the investment committee of Mithril GP. The investment committee makes all investment decisions with respect to shares held by Mithril I and may be deemed to have shared voting, investment and dispositive power with respect to these securities.

    (2)

    Based on 47,927,214 shares of the Issuer’s common stock (“Common Stock”) outstanding as of August 2, 2024 as set forth in the Issuer’s quarterly report on Form 10-Q for the quarter ended June 30, 2024, filed with the United States Securities and Exchange Commission (the “Commission”) on August 14, 2024 (the “Form 10-Q”).


    CUSIP No. 35168W103      

    13G

     

     1.   

     Name of Reporting Persons

     

     Mithril GP LP

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC Use Only

     

     4.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.    

     Sole Voting Power

     

     0

       6.   

     Shared Voting Power

     

     5,160,301 shares of common stock (1)

       7.   

     Sole Dispositive Power

     

     0

       8.   

     Shared Dispositive Power

     

     5,160,301 shares of common stock (1)

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     5,160,301 shares of common stock (1)

    10.  

     Check if the Aggregate Amount in Row 9 Excludes Certain Shares (See Instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row 9

     

     10.8% (2)

    12.  

     Type of Reporting Person (See Instructions)

     

     PN

     

     

    (1)

    All such shares are held of record by Mithril I. Mithril GP is the general partner of Mithril I and Mithril GP may be deemed to have shared voting, investment and dispositive power with respect to these securities. Ajay Royan is the authorized person of Mithril GP. Ajay Royan and Peter Thiel are the members of the investment committee of Mithril GP. The investment committee makes all investment decisions with respect to shares held by Mithril I and may be deemed to have shared voting, investment and dispositive power with respect to these securities.

    (2)

    Based on 47,927,214 shares of Common Stock outstanding as of August 2, 2024, as set forth in the Form 10-Q.


    CUSIP No. 35168W103      

    13G

     

     1.   

     Name of Reporting Persons

     

     Mithril II LP

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC Use Only

     

     4.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.    

     Sole Voting Power

     

     0

       6.   

     Shared Voting Power

     

     1,251,900 shares of common stock (1)

       7.   

     Sole Dispositive Power

     

     0

       8.   

     Shared Dispositive Power

     

     1,251,900 shares of common stock (1)

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     1,251,900 shares of common stock (1)

    10.  

     Check if the Aggregate Amount in Row 9 Excludes Certain Shares (See Instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row 9

     

     2.6% (2)

    12.  

     Type of Reporting Person (See Instructions)

     

     PN

     

     

    (1)

    All such shares are held of record by Mithril II (as defined in Item 2(a) below). Mithril II UGP (as defined in Item 2(a) below) is the general partner of Mithril II GP (as defined in Item 2(a) below), which is the general partner of Mithril II, and each of Mithril II UGP and Mithril II GP may be deemed to have shared voting, investment, and dispositive power with respect to the shares held by Mithril II. Ajay Royan is the sole managing member of Mithril II UGP. Ajay Royan and Peter Thiel are the members of the investment committee established by Mithril II GP. The investment committee makes all investment decisions with respect to the shares held by Mithril II and may be deemed to have shared voting, investment and dispositive power with respect to such shares.

    (2)

    Based on 47,927,214 shares of Common Stock outstanding as of August 2, 2024, as set forth in the Form 10-Q.


    CUSIP No. 35168W103      

    13G

     

     1.   

     Name of Reporting Persons

     

     Mithril II GP LP

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC Use Only

     

     4.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.    

     Sole Voting Power

     

     0

       6.   

     Shared Voting Power

     

     1,251,900 shares of common stock (1)

       7.   

     Sole Dispositive Power

     

     0

       8.   

     Shared Dispositive Power

     

     1,251,900 shares of common stock (1)

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     1,251,900 shares of common stock (1)

    10.  

     Check if the Aggregate Amount in Row 9 Excludes Certain Shares (See Instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row 9

     

     2.6% (2)

    12.  

     Type of Reporting Person (See Instructions)

     

     PN

     

     

    (1)

    All such shares are held of record by Mithril II. Mithril II UGP is the general partner of Mithril II GP, which is the general partner of Mithril II, and each of Mithril II UGP and Mithril II GP may be deemed to have shared voting, investment, and dispositive power with respect to the shares held by Mithril II. Ajay Royan is the sole managing member of Mithril II UGP. Ajay Royan and Peter Thiel are the members of the investment committee established by Mithril II GP. The investment committee makes all investment decisions with respect to the shares held by Mithril II and may be deemed to have shared voting, investment and dispositive power with respect to such shares.

    (2)

    Based on 47,927,214 shares of Common Stock outstanding as of August 2, 2024, as set forth in the Form 10-Q.


    CUSIP No. 35168W103      

    13G

     

     1.   

     Name of Reporting Persons

     

     Mithril II UGP LLC

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC Use Only

     

     4.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.    

     Sole Voting Power

     

     0

       6.   

     Shared Voting Power

     

     1,251,900 shares of common stock (1)

       7.   

     Sole Dispositive Power

     

     0

       8.   

     Shared Dispositive Power

     

     1,251,900 shares of common stock (1)

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     1,251,900 shares of common stock (1)

    10.  

     Check if the Aggregate Amount in Row 9 Excludes Certain Shares (See Instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row 9

     

     2.6% (2)

    12.  

     Type of Reporting Person (See Instructions)

     

     OO

     

     

    (1)

    All such shares are held of record by Mithril II. Mithril II UGP is the general partner of Mithril II GP, which is the general partner of Mithril II, and each of Mithril II UGP and Mithril II GP may be deemed to have shared voting, investment, and dispositive power with respect to the shares held by Mithril II. Ajay Royan is the sole managing member of Mithril II UGP. Ajay Royan and Peter Thiel are the members of the investment committee established by Mithril II GP. The investment committee makes all investment decisions with respect to the shares held by Mithril II and may be deemed to have shared voting, investment and dispositive power with respect to such shares.

    (2)

    Based on 47,927,214 shares of Common Stock outstanding as of August 2, 2024, as set forth in the Form 10-Q.


    CUSIP No. 35168W103      

    13G

     

     1.   

     Name of Reporting Persons

     

     Ajay Royan

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC Use Only

     

     4.  

     Citizenship or Place of Organization

     

     Canada

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.    

     Sole Voting Power

     

     0

       6.   

     Shared Voting Power

     

     6,412,201 shares of common stock (1)

       7.   

     Sole Dispositive Power

     

     0

       8.   

     Shared Dispositive Power

     

     6,412,201 shares of common stock (1)

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     6,412,201 shares of common stock (1)

    10.  

     Check if the Aggregate Amount in Row 9 Excludes Certain Shares (See Instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row 9

     

     13.4% (2)

    12.  

     Type of Reporting Person (See Instructions)

     

     IN

     

     

    (1)

    Includes (i) 5,160,301 shares held by Mithril I and (ii) 1,251,900 shares held by Mithril II. Mithril GP is the general partner of Mithril I and Mithril GP may be deemed to have shared voting, investment and dispositive power with respect to the securities held by Mithril I. Mithril II UGP is the general partner of Mithril II GP, which is the general partner of Mithril II, and each of Mithril II UGP and Mithril II GP may be deemed to have shared voting, investment and dispositive power with respect to the securities held by Mithril II. Ajay Royan is the authorized person of Mithril I GP and is the sole managing member of Mithril II UGP. Ajay Royan and Peter Thiel are the members of the investment committee of Mithril GP and the members of the investment committee established by Mithril II GP. Each of the investment committees makes all investment decisions with respect to the shares held by each of Mithril I and Mithril II, respectively, and may be deemed to have shared voting, investment and dispositive power with respect to the securities held by each of Mithril I and Mithril II.

    (2)

    Based on 47,927,214 shares of Common Stock outstanding as of August 2, 2024, as set forth in the Form 10-Q.


    CUSIP No. 35168W103      

    13G

     

     1.   

     Name of Reporting Persons

     

     Peter Thiel

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC Use Only

     

     4.  

     Citizenship or Place of Organization

     

     United States of America

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.    

     Sole Voting Power

     

     0

       6.   

     Shared Voting Power

     

     6,412,201 shares of common stock (1)

       7.   

     Sole Dispositive Power

     

     0

       8.   

     Shared Dispositive Power

     

     6,412,201 shares of common stock (1)

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     6,412,201 shares of common stock (1)

    10.  

     Check if the Aggregate Amount in Row 9 Excludes Certain Shares (See Instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row 9

     

     13.4% (2)

    12.  

     Type of Reporting Person (See Instructions)

     

     IN

     

     

    (1)

    Includes (i) 5,160,301 shares held by Mithril I and (ii) 1,251,900 shares held by Mithril II. Mithril GP is the general partner of Mithril I and Mithril GP may be deemed to have shared voting, investment and dispositive power with respect to the securities held by Mithril I. Mithril II UGP is the general partner of Mithril II GP, which is the general partner of Mithril II, and each of Mithril II UGP and Mithril II GP may be deemed to have shared voting, investment and dispositive power with respect to the securities held by Mithril II. Ajay Royan is the authorized person of Mithril I GP and is the sole managing member of Mithril II UGP. Ajay Royan and Peter Thiel are the members of the investment committee of Mithril GP and the members of the investment committee established by Mithril II GP. Each of the investment committees makes all investment decisions with respect to the shares held by each of Mithril I and Mithril II, respectively, and may be deemed to have shared voting, investment and dispositive power with respect to the securities held by each of Mithril I and Mithril II.

    (2)

    Based on 47,927,214 shares of Common Stock outstanding as of August 2, 2024, as set forth in the Form 10-Q.


    Introductory Note: This joint statement on Schedule 13G (this “Statement”) is filed on behalf of the Reporting Persons, in respect of shares of Common Stock, par value $0.00001 per share, of Fractyl Health, Inc. (the “Issuer”).

     

    Item 1(a).

    Name of Issuer:

    Fractyl Health, Inc.

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    3 Van de Graaff Drive, Suite 200

    Burlington, MA 01803

     

    Item 2(a).

    Name of Person Filing:

    This Statement is being filed by Mithril LP (“Mithril I”), Mithril GP LP (“Mithril GP”) Mithril II LP (“Mithril II”), Mithril II GP LP (“Mithril II GP”), Mithril II UGP LLC (“Mithril II UGP”, and together with Mithril I, Mithril GP, Mithril II and Mithril II GP LP, the “Reporting Entities”), Ajay Royan (“Royan”) and Peter Thiel (“Thiel”, and together with Royan, the “Reporting Individuals”). The Reporting Entities and the Reporting Individuals are collectively referred to as the “Reporting Persons”.

     

    Item 2(b)

    Address of Principal Business Office, or if None, Residence:

    The address of the principal business office of each Reporting Entity and the business address of each Reporting Individual is c/o Mithril Capital Management LLC, 111 Congress Ave., Suite 500, Austin, TX 78701.

     

    Item 2(c).

    Citizenship:

    Mithril II UGP is a limited liability company organized under the laws of the State of Delaware. Each of Mithril I, Mithril GP, Mithril II and Mithril II GP is a limited partnership organized under the laws of the State of Delaware. Royan is a citizen of Canada. Thiel is a citizen of the United States of America.

     

    Item 2(d).

    Title of Class of Securities:

    Common Stock, $0.00001 par value per share.

     

    Item 2(e).

    CUSIP Number:

    35168W103

     

    Item 3.

    If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

    Not applicable.

     

    Item 4.

    Ownership.

     

      (a)

    Amount beneficially owned:

    See Row 9 of the cover page for each Reporting Person.*

     

      (b)

    Percent of class:

    See Row 11 of the cover page for each Reporting Person and the corresponding footnotes.*


      (c)

    Number of shares as to which the person has:

     

      (i)

    Sole power to vote or to direct the vote

    See Row 5 of the cover page for each Reporting Person and the corresponding footnotes.*

     

      (ii)

    Shared power to vote or to direct the vote

    See Row 6 of the cover page for each Reporting Person and the corresponding footnotes.*

     

      (iii)

    Sole power to dispose or to direct the disposition of

    See Row 7 of the cover page for each Reporting Person and the corresponding footnotes.*

     

      (iv)

    Shared power to dispose or to direct the disposition of

    See Row 8 of the cover page for each Reporting Person and the corresponding footnotes.*

     

    *

    Except to the extent of their pecuniary interest therein, each Reporting Person disclaims beneficial ownership of such shares of Common Stock, except for the shares, if any, such Reporting Person holds of record.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    Not applicable.

     

    Item 6.

    Ownership of More Than Five Percent on Behalf of Another Person.

    Under certain circumstances set forth in the limited partnership agreements of each of Mithril I, Mithril GP, Mithril II and Mithril II GP and the limited liability company agreement of Mithril II UGP, the general and limited partners or members, as the case may be, of each of such entities may be deemed to have the right to receive dividends from, or the proceeds from, the sale of securities of the Issuer owned by each such entity of which they are a partner or member, as the case may be.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not applicable.

     

    Item 9.

    Notice of Dissolution of the Group.

    Not applicable.

     

    Item 10.

    Certifications.

    Not applicable.

    Material to be Filed as Exhibits.

    Exhibit 1 – Joint Filing Agreement.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    November 13, 2024

     

    Mithril LP
    By:   Mithril GP LP
    Its:   General Partner
    By:   /s/ Ajay Royan
      Ajay Royan, Authorized Person
    Mithril GP LP
    By:   /s/ Ajay Royan
      Ajay Royan, Authorized Person
    Mithril II LP
    By:   Mithril II GP LP
    Its:   General Partner
    By:   Mithril II UGP LLC
    Its:   General Partner
    By:   /s/ Ajay Royan
      Ajay Royan, Managing Member
    Mithril II GP LP
    By:   Mithril II UGP LLC
    Its:   General Partner
    By:   /s/ Ajay Royan
      Ajay Royan Managing Member
    Mithril II UGP LLC
    By:   /s/ Ajay Royan
      Ajay Royan, Managing Member
      /s/ Ajay Royan
      Ajay Royan
      /s/ Peter Thiel
      Peter Thiel
    Get the next $GUTS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GUTS

    DatePrice TargetRatingAnalyst
    2/28/2024Outperform
    Evercore ISI
    2/27/2024$18.00Overweight
    Morgan Stanley
    2/27/2024$26.00Buy
    BofA Securities
    More analyst ratings

    $GUTS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Fractyl Health Inc.

      SC 13G - FRACTYL HEALTH, INC. (0001572616) (Subject)

      11/14/24 4:30:50 PM ET
      $GUTS
    • SEC Form SC 13G filed by Fractyl Health Inc.

      SC 13G - FRACTYL HEALTH, INC. (0001572616) (Subject)

      11/13/24 5:17:27 PM ET
      $GUTS
    • SEC Form SC 13G filed by Fractyl Health Inc.

      SC 13G - Fractyl Health, Inc. (0001572616) (Subject)

      2/16/24 9:43:25 PM ET
      $GUTS

    $GUTS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form 4 filed by Director Conaway Samuel

      4/A - FRACTYL HEALTH, INC. (0001572616) (Issuer)

      3/18/25 8:18:31 PM ET
      $GUTS
    • Director Royan Ajay bought $22,980 worth of shares (17,901 units at $1.28) (SEC Form 4)

      4 - FRACTYL HEALTH, INC. (0001572616) (Issuer)

      3/18/25 7:57:09 PM ET
      $GUTS
    • Director Barnes Kelly Ann bought $40,210 worth of shares (31,000 units at $1.30) (SEC Form 4)

      4 - FRACTYL HEALTH, INC. (0001572616) (Issuer)

      3/18/25 4:50:44 PM ET
      $GUTS

    $GUTS
    SEC Filings

    See more
    • Fractyl Health Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - FRACTYL HEALTH, INC. (0001572616) (Filer)

      5/19/25 9:27:21 AM ET
      $GUTS
    • Fractyl Health Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - FRACTYL HEALTH, INC. (0001572616) (Filer)

      5/19/25 7:00:08 AM ET
      $GUTS
    • Fractyl Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - FRACTYL HEALTH, INC. (0001572616) (Filer)

      5/13/25 4:05:11 PM ET
      $GUTS

    $GUTS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Fractyl Health Advances Rejuva® Gene Therapy Platform with Submission of First Clinical Trial Application Module in Europe for RJVA-001 in Type 2 Diabetes

      First-in-human study will evaluate safety, tolerability, and early efficacy of a one-time, pancreas-targeted smart GLP-1TM gene therapy for patients with inadequately controlled T2D and obesity Expect to dose first patients and report preliminary data in 2026, pending CTA authorization BURLINGTON, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the Company), a metabolic therapeutics company pioneering pattern-breaking treatments for obesity and type 2 diabetes (T2D), today announced that it has submitted the first module of its Clinical Trial Application (CTA) in Europe for RJVA-001, the Company's gene therapy candidate from its Rejuva platform. RJVA-001 is de

      5/19/25 7:00:00 AM ET
      $GUTS
    • Fractyl Health Announces First Quarter 2025 Financial Results and Business Updates

      REVEAL-1 Cohort 3-month open-label data update expected in June 2025; early clinical signals reinforce Revita's potential to maintain weight loss after GLP-1 discontinuation in the real world REMAIN-1 Midpoint Cohort data expected in Q3 2025; first randomized data on post-GLP-1 weight maintenance REMAIN-1 Pivotal Cohort has completed enrollment ahead of schedule; 6-month primary endpoint data anticipated in H2 2026 Rejuva gene therapy platform advancing toward first-in-human studies; first CTA module submission for RJVA-001 expected in June 2025 Conference call today at 4:30 p.m. ET BURLINGTON, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) ("the Company"),

      5/13/25 4:05:00 PM ET
      $GUTS
    • Fractyl Health to Report First Quarter 2025 Financial Results and Provide Business Updates on May 13, 2025, and Will Participate in an Upcoming Investor Conference

      BURLINGTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the "Company"), a metabolic therapeutics company focused on pattern breaking approaches that treat root causes of obesity and type 2 diabetes (T2D), today announced it will report financial results for the first quarter 2025 and provide business updates on Tuesday, May 13, 2025, at 4:30 p.m. ET. A live webcast of the conference call can be accessed in the "Events" section of Fractyl Health's website at http://ir.fractyl.com. The webcast will be archived and available for replay following the live event. The Company also announced that Harith Rajagopalan, M.D., Ph.D., Co-Founder and Chief Executive Off

      5/6/25 7:00:00 AM ET
      $GUTS

    $GUTS
    Financials

    Live finance-specific insights

    See more
    • Fractyl Health Announces First Quarter 2025 Financial Results and Business Updates

      REVEAL-1 Cohort 3-month open-label data update expected in June 2025; early clinical signals reinforce Revita's potential to maintain weight loss after GLP-1 discontinuation in the real world REMAIN-1 Midpoint Cohort data expected in Q3 2025; first randomized data on post-GLP-1 weight maintenance REMAIN-1 Pivotal Cohort has completed enrollment ahead of schedule; 6-month primary endpoint data anticipated in H2 2026 Rejuva gene therapy platform advancing toward first-in-human studies; first CTA module submission for RJVA-001 expected in June 2025 Conference call today at 4:30 p.m. ET BURLINGTON, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) ("the Company"),

      5/13/25 4:05:00 PM ET
      $GUTS
    • Fractyl Health to Report First Quarter 2025 Financial Results and Provide Business Updates on May 13, 2025, and Will Participate in an Upcoming Investor Conference

      BURLINGTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the "Company"), a metabolic therapeutics company focused on pattern breaking approaches that treat root causes of obesity and type 2 diabetes (T2D), today announced it will report financial results for the first quarter 2025 and provide business updates on Tuesday, May 13, 2025, at 4:30 p.m. ET. A live webcast of the conference call can be accessed in the "Events" section of Fractyl Health's website at http://ir.fractyl.com. The webcast will be archived and available for replay following the live event. The Company also announced that Harith Rajagopalan, M.D., Ph.D., Co-Founder and Chief Executive Off

      5/6/25 7:00:00 AM ET
      $GUTS
    • Fractyl Health Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates

      Strong patient and physician demand for pivotal REMAIN-1 study highlights urgent need for post-GLP-1 withdrawal weight maintenance solutions; midpoint data analysis anticipated in Q2 2025 and full study enrollment expected in summer 2025 Company plans to submit first Clinical Trial Application (CTA) module for RJVA-001 in type 2 diabetes to regulators in H1 2025, and if CTA is authorized, expects to report preliminary data in 2026 Conference call today at 4:30 p.m. ET BURLINGTON, Mass., March 03, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) ("the Company"), a metabolic therapeutics company focused on pioneering new approaches that treat root causes of obesity and Type 2 D

      3/3/25 4:05:00 PM ET
      $GUTS

    $GUTS
    Leadership Updates

    Live Leadership Updates

    See more
    • Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes

      BURLINGTON, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the "Company"), a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes (T2D), today announced the appointment of Adrian Kimber as Chief Commercial Officer. Mr. Kimber joins Fractyl with over two decades of experience in the biotechnology and medical devices sectors. Throughout his career, he has showcased a commendable history of introducing groundbreaking therapies to worldwide markets. Renowned for his adeptness in formulating go-to-market strategies, assembling and leading commercial teams, and implementing operational excellence, he

      4/2/24 8:00:00 AM ET
      $GUTS
    • Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita® Pivotal Clinical Trials

      LEXINGTON, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) ("Fractyl Health" or the "Company"), a metabolic therapeutics company focused on pioneering new approaches for the treatment of Type 2 Diabetes (T2D) and obesity, today announced the appointment of Samuel Conaway to its Board of Directors. Mr. Conaway's extensive background in the commercialization of medical technologies and leadership in new product launches will provide valuable insight and experience as Fractyl Health advances through pivotal clinical studies for T2D and weight loss maintenance and continues its ongoing pilot launch and real-world registry study of Revita in Germany. "Sam Conaway's

      2/20/24 8:38:00 AM ET
      $GUTS

    $GUTS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Royan Ajay bought $22,980 worth of shares (17,901 units at $1.28) (SEC Form 4)

      4 - FRACTYL HEALTH, INC. (0001572616) (Issuer)

      3/18/25 7:57:09 PM ET
      $GUTS
    • Director Barnes Kelly Ann bought $40,210 worth of shares (31,000 units at $1.30) (SEC Form 4)

      4 - FRACTYL HEALTH, INC. (0001572616) (Issuer)

      3/18/25 4:50:44 PM ET
      $GUTS
    • Director Schulman Amy W bought $9,964 worth of shares (8,550 units at $1.17) (SEC Form 4)

      4 - FRACTYL HEALTH, INC. (0001572616) (Issuer)

      3/17/25 5:09:08 PM ET
      $GUTS

    $GUTS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Evercore ISI initiated coverage on Fractyl Health

      Evercore ISI initiated coverage of Fractyl Health with a rating of Outperform

      2/28/24 8:22:09 AM ET
      $GUTS
    • Morgan Stanley initiated coverage on Fractyl Health with a new price target

      Morgan Stanley initiated coverage of Fractyl Health with a rating of Overweight and set a new price target of $18.00

      2/27/24 6:55:29 AM ET
      $GUTS
    • BofA Securities initiated coverage on Fractyl Health with a new price target

      BofA Securities initiated coverage of Fractyl Health with a rating of Buy and set a new price target of $26.00

      2/27/24 6:55:03 AM ET
      $GUTS